REstore Working Ability in RheumatoiD Arthritis (REWARD)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by The Rheumatological Center of Helsinki.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Abbott
Information provided by:
The Rheumatological Center of Helsinki
ClinicalTrials.gov Identifier:
NCT01405326
First received: June 30, 2011
Last updated: July 28, 2011
Last verified: July 2011

June 30, 2011
July 28, 2011
May 2011
December 2012   (final data collection date for primary outcome measure)
Number of lost work days due to RA during the 6-month follow up. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01405326 on ClinicalTrials.gov Archive Site
  • Change in health-related quality of life as measured by the EQ-5D index over the 6-month follow up [ Time Frame: baseline and 6 months ] [ Designated as safety issue: No ]
  • Change in functionality assessed by the HAQ over the 6-month follow up [ Time Frame: baseline and 6 months ] [ Designated as safety issue: No ]
  • Change in disease activity measured with DAS28 with CRP and ESR over the 6-month follow up [ Time Frame: baseline and 6 months ] [ Designated as safety issue: No ]
  • Work Productivity and Activity Impairment Questionnaire (WPAI) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
REstore Working Ability in RheumatoiD Arthritis
The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work

The purpose of the study is to assess whether a 6-month treatment with adalimumab added on the treatment with conventional antirheumatic drugs (DMARD) will decrease the number of days on sick leave compared to placebo. In addition, the cost-effectiveness and cost-utility of the intervention compared to the conventional treatment is evaluated, and the patients who benefit most are characterized.

In spite of the improved medical treatment, rheumatoid arthritis (RA) is still causing both significant morbidity and marked loss of work productivity. Short periods of work inability, i.e., sick leaves represent a significant part of the socioeconomic burden of RA. The study is a randomized, controlled double blind multi-center study. 160 patients of 25 to 55 years of age with recent-onset (≤2 years from diagnosis) RA who have been treated with a combination of conventional antirheumatic drugs but have an inadequate response to treatment and are at the risk of losing their ability to work, are enrolled. The patients should be biologic-naïve. Their RA should be active, but not so active that the conventional criteria for biologic therapy would be fulfilled. The subjects are randomized at 1:1 ratio to receive either adalimumab (40 mg every two weeks) or placebo for 6 months added on their concurrent antirheumatic therapy. The RA-related sickness absence and clinical response will be evaluated.

Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Rheumatoid Arthritis
Biological: adalimumab
40mg sc. every two weeks for six months
Other Name: Humira
  • Experimental: Adalimumab
    Adalimumab treatment for 6 months
    Intervention: Biological: adalimumab
  • Placebo Comparator: Pacebo
    Corresponding placebo for active treatment group
    Intervention: Biological: adalimumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
160
March 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR) criteria
  2. Time from diagnosis of RA < 2 years
  3. Age 25-55 years
  4. Active RA with at least 3 active joints (tender and/or swollen joints)
  5. Stable DMARD combination treatment for more than 3 months
  6. At least one of the following

    • Rheumatoid factor positive
    • One or more erosions in x-rays of the hands and feet
    • Anti-citrulline antibodies positive
  7. At least other of the following

    • HAQ-index 0.5 or more
    • Patient or physician evaluation of RA activity >25 mm (VAS 0-10 cm)
  8. Patient has been steadily in work-life for at least one year and is currently working or on sick- leave but not applying for pension
  9. Patient feels that he/she will likely have to be off-work during the following 6 months due to his/her RA
  10. Patient must be willing and able to provide written informed consent for the trial
  11. Each female subject must agree to use a medically accepted method of contraception while receiving study medication

Exclusion Criteria:

  1. A subject must not have a history of biological drug use for RA
  2. A subject must not have evidence of active or latent tuberculosis,
  3. A subject must not have any history of lymphoproliferative disease or malignancy within the previous 5 years
  4. A subject must not have any other condition, that according to the investigator's judgment makes him or her non-eligible for anti-TNF use
  5. A subject must not have any inflammatory rheumatic disease other than RA
  6. A subject must not have received any other investigational agents within 30 days prior to baseline visit, and must not receive them during the current trial
  7. A female subject must not be pregnant or breast-feeding or planning pregnancy during the study
  8. A subject must not have had a major surgery within one month prior to study entry and must not have a scheduled operation during the 6-month follow up
  9. A subject must not have any clinically significant condition or situation, other than the condition being studied, that in the opinion of the investigator would interfere with the optimal participation in the trial.
  10. A subject must not fulfill the criteria for reimbursement for biologics for RA and he/she would not normally be prescribed a biological drug according to physicians discretion and national treatment guidelines
  11. A patient must not be currently on reimbursed rehabilitation period, or such period must not be scheduled for the next six months
Both
25 Years to 55 Years
No
Contact: Kari K Eklund, MD +358405832866 kari.eklund@welho.com
Contact: Kari Puolakka, MD +358408354734 kari.puolakka@eksote.fi
Finland
 
NCT01405326
RE100002011
No
Kari Eklund MD, Chief of medical affairs, The Rheumatological Center of Helsinki
The Rheumatological Center of Helsinki
Abbott
Principal Investigator: Kari K Eklund, MD The Rheumatological Center of Helsinki
The Rheumatological Center of Helsinki
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP